@article {CHO3541, author = {OYEON CHO and MISON CHUN and SUK-JOON CHANG and YOUNG-TAEK OH and O KYU NOH}, title = {Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer}, volume = {36}, number = {7}, pages = {3541--3547}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (\<200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. Patients and Methods: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. Results: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95\% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (>=200 cells/μl) than among those with grade 4 lymphopenia (84.8\% vs. 50.4\%, p\<0.001, and 80.7\% vs. 50\%, p=0.002, respectively). Conclusion: Severe lymphopenia during CCRT could predict poor survival.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/7/3541}, eprint = {https://ar.iiarjournals.org/content/36/7/3541.full.pdf}, journal = {Anticancer Research} }